Physician profile
Thomas E Lowe
NPI 1801968334
$2,005.81
in general payments reported to CMS, 2019-2025
23 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.08 · 2022: $87.59 · 2023: $552 · 2024: $744 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.14 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $515.38 | 2022-2025 | Calquence, Farxiga |
| Genentech USA, INC. | $252.35 | 2023-2025 | Tecentriq, Polivy, Lunsumio |
| Eisai INC. | $213.02 | 2023-2024 | |
| Dendreon Pharmaceuticals LLC | $165.06 | 2024 | Provenge |
| Pfizer INC. | $146.28 | 2022-2024 | |
| Array Biopharma INC | $133.40 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Merck Sharp & Dohme LLC | $68.03 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $64.73 | 2023-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $60.89 | 2023-2024 | Jemperli, Zejula |
| Puma Biotechnology, INC. | $60.47 | 2025 | |
| Janssen Biotech, INC. | $49.87 | 2025 | Erleada, Balversa, Akeega |
| Abbvie INC. | $48.40 | 2023-2024 | |
| Amgen INC. | $43.49 | 2021-2023 | Lumakras |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Aimmune Therapeutics, INC. | $30.77 | 2025 | Vowst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.38 | 2021 | |
| Kyowa Kirin, INC. | $22.02 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.41 | 2025 | |
| Mylan Institutional INC. | $20.11 | 2022 | |
| Apellis Pharmaceuticals, INC. | $14.98 | 2025 | Empaveli |
| Tactile Systems Technology INC | $11.77 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.